patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Back To Forum List View

bankerson

Rank: Treasurer [?]

Points: 22820 [?]

Votes: 138 Score: 2.9 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

news more news

posted on Mar 06, 2014 09:26AM

Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.

Article Preview — For full access, register below, it's free

By George Budwell | More Articles
March 6, 2014 | Comments (0)

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a look at the top stories in biotech and health care this morning -- keep an eye out for Pluristem Therapeutics (NASDAQ: PSTI ) , Rigel Pharmaceuticals (NASDAQ: RIGL ) , and Sangamo Biosciences (NASDAQ: SGMO )

Pluristem heading higher on FDA approval of placental-based cell products manufacturing facility
Pluristem looks to be in for a good day after receiving approval to manufacture its PLacental eXpanded cell products in its new commercial-scale cell manufacturing facility from the U.S. Food and Drug Administration, or FDA. This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January. Shares of Pluristem are up over 6% in premarket on this news.